Literature DB >> 26642343

Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.

J Aoki1, S Seo2, H Kanamori1, M Tanaka1, T Fukuda3, M Onizuka4, N Kobayashi5, T Kondo6, M Sawa7, N Uchida8, K Iwato9, T Icihnohe10, Y Atsuta11,12, S Yano13, A Takami14.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26642343     DOI： 10.1038/bmt.2015.297

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

Review 1.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

Review 2.  Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.

Authors:  A J Barrett; B N Savani
Journal:  Leukemia       Date:  2006-07-27       Impact factor: 11.528

Review 3.  Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

Authors:  H M Lazarus; J M Rowe
Journal:  Leukemia       Date:  2006-07-27       Impact factor: 11.528

4.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Authors:  Boglarka Gyurkocza; Rainer Storb; Barry E Storer; Thomas R Chauncey; Thoralf Lange; Judith A Shizuru; Amelia A Langston; Michael A Pulsipher; Christopher N Bredeson; Richard T Maziarz; Benedetto Bruno; Finn B Petersen; Michael B Maris; Edward Agura; Andrew Yeager; Wolfgang Bethge; Firoozeh Sahebi; Frederick R Appelbaum; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 5.  TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions.

Authors:  C E Hill-Kayser; J P Plastaras; Z Tochner; E Glatstein
Journal:  Bone Marrow Transplant       Date:  2010-11-29       Impact factor: 5.483

6.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Authors:  M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

7.  Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.

Authors:  Andrea Bacigalupo; Gerard Socie'; Edoardo Lanino; Arcangelo Prete; Franco Locatelli; Anna Locasciulli; Simone Cesaro; Avichai Shimoni; Judith Marsh; Mats Brune; Maria Teresa Van Lint; Rosi Oneto; Jacob Passweg
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Authors:  James A Russell; William Irish; Alexander Balogh; M Ahsan Chaudhry; Mary Lynn Savoie; A Robert Turner; Loree Larratt; Jan Storek; Nizar J Bahlis; Christopher B Brown; Diana Quinlan; Michelle Geddes; Nancy Zacarias; Andrew Daly; Peter Duggan; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-03       Impact factor: 5.742

10.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742
View more
  6 in total

1.  Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.

Authors:  Tomoaki Ueda; Tomoyasu Jo; Kazuya Okada; Yasuyuki Arai; Takayuki Sato; Takeshi Maeda; Tatsuhito Onishi; Yasunori Ueda
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

Review 2.  Hematopoietic stem cell transplantation for acute myeloid leukemia.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

3.  Microarray Expression Profile of lncRNAs and mRNAs in Rats with Traumatic Brain Injury after A2B5+ Cell Transplantation.

Authors:  Qiang Lyu; Zi-Bin Zhang; Song-Jun Fu; Liu-Lin Xiong; Jing Liu; Ting-Hua Wang
Journal:  Cell Transplant       Date:  2017-10       Impact factor: 4.064

4.  National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: The Japanese Radiation Oncology Study Group.

Authors:  Hiroki Kawaguchi; Toshinori Soejima; Naoya Ishibashi; Takeshi Akiba; Masatoshi Hasegawa; Kouichi Isobe; Hitoshi Ito; Michiko Imai; Yasuo Ejima; Masaharu Hata; Keisuke Sasai; Emiko Shimoda; Masahiko Oguchi; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724

5.  Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.

Authors:  Johannes Schetelig; Jan Moritz Middeke; Katja Sockel; Friedrich Stölzel; Franziska Hönl; Henning Baldauf; Christoph Röllig; Martin Wermke; Malte von Bonin; Raphael Teipel; Cornelia Link-Rachner; Kalina Brandt; Frank Kroschinsky; Mathias Hänel; Anke Morgner; Christian Klesse; Gerhard Ehninger; Uwe Platzbecker; Martin Bornhäuser
Journal:  Cancer Manag Res       Date:  2022-02-15       Impact factor: 3.989

6.  Low-dose total body irradiation facilitates antitumoral Th1 immune responses.

Authors:  Dominik Sonanini; Christoph M Griessinger; Barbara F Schörg; Philipp Knopf; Klaus Dittmann; Martin Röcken; Bernd J Pichler; Manfred Kneilling
Journal:  Theranostics       Date:  2021-06-16       Impact factor: 11.556
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.